Breaking News Instant updates and real-time market news.

TLRY

Tilray

$22.00

1.35 (6.54%)

10:05
10/15/19
10/15
10:05
10/15/19
10:05

Tilray call volume above normal and directionally bullish

Bullish option flow detected in Tilray with 5,765 calls trading, 3x expected, and implied vol increasing over 5 points to 99.29%. 11/8 weekly 19 calls and Oct-19 22 calls are the most active options, with total volume in those strikes near 1,500 contracts. The Put/Call Ratio is 0.34. Earnings are expected on November 13th.

  • 12

    Nov

TLRY Tilray
$22.00

1.35 (6.54%)

09/26/19
COMP
09/26/19
NO CHANGE
COMP
Cannabis banking bill should find path to passage in Senate, says Compass Point
After the House of Representatives cleared the SAFE Banking Act by a vote of 321 to 103, Compass Point analyst Isaac Boltansky said the bipartisan clearance of the cannabis banking bill should be viewed as a tailwind for the bill's prospects in the Senate and he continue to think it will find "a path to passage" as part of a broader legislative package. He thinks that the SAFE Act will expand access to banking services for legal cannabis operators, but cautions that any immediate expansion is likely to be modest. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), and Trulieve Cannabis (TCNNF).
10/09/19
ROTH
10/09/19
NO CHANGE
ROTH
Roth says low enthusiasm for cannabis stocks doesn't reflect industry potential
Roth Capital analyst Scott Fortune noted that stocks in the cannabis sector have declined during the six months since the first quarter with the industry "mired in a capital crunch, with a vape crisis to make matters worse." However, he thinks the recently lower enthusiasm for cannabis stocks does not reflect the cannabis industry's prospects, as he still sees a lot of upside potential. A "meaningful shift" in investor focus to operational execution has led to a short-term correction in valuations, but the industry is still projected to grow at a 27% compound annual growth rate for the next three years, said Fortune, who advises that investors focus for now on companies with strong balance sheets and positive adjusted EBITDA who are nearing break even. Publicly traded companies in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Tilray (TLRY), and Trulieve Cannabis (TCNNF).
10/10/19
STFL
10/10/19
NO CHANGE
STFL
Hexo miss further damages cannabis industry credibility, says Stifel
Hexo (HEXO) this morning provided a preliminary update for its fiscal Q4 with revenue coming in below the consensus estimate and well below the "double" offered by management mid-quarter during the Q3 earnings call, Stifel analyst Andrew Carter tells investors in a research note. The preannouncement is "another headline damaging" the cannabis industry's credibility, Carter tells investors in a research note. For companies facing "significant financing risk," the analyst believes a "real segregation of assets will occur." Some companies will face significant dilution due to onerous financing terms while others will simply be unable to access capital, predicts the analyst. Carter thinks the macro environment will continue to be difficult and that the capital positions of Canopy Growth (CGC) and Cronos Group (CRON) are "clear competitive advantages." Those two have the ability to continue executing their business plans while capitalizing on the sector weakness, which "will only intensify from here," says Carter. Other names in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Zynerba (ZYNE). Shares of Hexo are down 24%, or 90c, to $2.78 in early trading.
10/14/19
GHSC
10/14/19
DOWNGRADE
GHSC
Neutral
Canopy, Hexo downgraded to Neutral as Seaport Global cuts cannabis estimates
Seaport Global analyst Brett Hundley lowered his sales and earnings forecasts for the conventional Canadian cannabis companies he covers as part of a broader reset of expectations for the Canadian cannabis space. As part of the broader changes, he downgraded Canopy Growth (CGC) and Hexo Corp. (HEXO), both to Neutral from Buy. Hundley has lowered his FY21 view for Canopy's revenue to $475.5M and his EBITDA forecast to ($75.1M), adding that he no longer feels confident in the company's potential to receive incremental equity warrant funding from Constellation (STZ) in the near-term. For Hexo, he now sees FY21 revenue of $121.7M and $0.2M in EBITDA. He expects market pricing to become "considerably more challenged" as industry production funnels into "a limited store set" in Canada, Hundley tells investors. He keeps a Buy rating on Aphria (APHA), making it his only Buy-rated conventional Canadian cannabis company, though he cut his price target on the stock to $8 from $13. Hundley has Neutral ratings on Aurora Cannabis (ACB) and Tilray (TLRY).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.